Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evexomostat - SynDevRx

Next Previous
Drug Profile

Evexomostat - SynDevRx

Alternative Names: MetAP2 inhibitor - SynDevRx; SDX-7320

Latest Information Update: 30 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SynDevRx, Inc
  • Developer Memorial Sloan-Kettering Cancer Center; SynDevRx, Inc
  • Class Antineoplastics; Cyclohexanes; Drug conjugates; Polymers; Sesquiterpenes; Unsaturated fatty acids
  • Mechanism of Action DNA synthesis inhibitors; Methionine aminopeptidase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Triple negative breast cancer
  • Phase I/II Breast cancer
  • Preclinical Colorectal cancer; Interstitial lung diseases
  • No development reported Solid tumours

Most Recent Events

  • 30 Jun 2026 Evexomostat is still in preclinical development in Colorectal-cancer in USA (Syndevrx pipeline, June 2026)
  • 30 Jun 2026 Syndevrx plans a EVEN-1 clinical trial for Prostate cancer (Second-line therapy or greater, Hormone refractory, Combination therapy) in the year 2026 (Syndevrx pipeline, June 2026)
  • 18 Jun 2026 SynDevRx in collaboration with Queensland University of Technology plans a phase I/II EVADE-1 trial for Prostate cancer (Hormone refractory, Metastatic cancer, Second-line therapy or greater) in Australia (SC, Injection) (ACTRN12626000736347p)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top